Tubulysin A (TubA): Potent Anticancer Agent and ADC Payload Supplier
Discover Tubulysin A (TubA), a highly potent cytotoxic peptide from myxobacteria. With proven anti-microtubule and anti-mitotic activity, TubA is a key component in cutting-edge Antibody-Drug Conjugate (ADC) therapies. We are a reliable manufacturer and supplier, offering high-purity Tubulysin A for your research and development needs. Get a competitive quote and sample today to advance your oncology drug discovery.
Get a Quote & SampleUnlocking Potent Anticancer Therapies with Tubulysin A
Tubulysin A (TubA)
As a premier supplier of pharmaceutical intermediates, we offer Tubulysin A (CAS 205304-86-5), a naturally derived cytotoxic peptide with exceptional potency. Tubulysin A functions as a potent inhibitor of tubulin polymerization, leading to cell cycle arrest and apoptosis, making it a critical component for novel anticancer drug development, particularly within Antibody-Drug Conjugates (ADCs). Our commitment as a manufacturer in China ensures quality and consistent supply for your critical research needs.
- High-Purity Tubulysin A for ADC Development: Source your critical ADC payload from a trusted manufacturer.
- Potent Anti-Microtubule and Anti-Mitotic Activity: Leverage TubA's mechanism for targeted cancer therapies.
- Reliable Manufacturer and Supplier in China: Ensure supply chain stability and competitive pricing.
- Facilitating Anticancer Drug Discovery: Accelerate your research with high-quality Tubulysin A.
Key Advantages of Sourcing Tubulysin A
Exceptional Cytotoxicity
Tubulysin A exhibits picomolar potency, significantly outperforming many established chemotherapeutics, making it an ideal choice for targeted cancer therapies like ADCs.
Mechanism of Action: Tubulin Inhibition
By effectively inhibiting tubulin polymerization, Tubulysin A disrupts microtubule dynamics, leading to cell cycle arrest at the G2/M phase and inducing apoptosis in cancer cells.
Proven ADC Payload Potential
Its high potency and unique mechanism make Tubulysin A a valuable payload for Antibody-Drug Conjugates (ADCs), enabling targeted delivery to tumor sites for enhanced efficacy and reduced systemic toxicity.
Applications of Tubulysin A in Pharmaceutical R&D
Oncology Drug Development
Explore the use of Tubulysin A as a novel anticancer agent, targeting various cancer cell lines with its potent antiproliferative and cytotoxic effects.
Antibody-Drug Conjugate (ADC) Design
Utilize TubA as a high-potency payload for ADCs, offering a promising strategy for targeted cancer treatment and improved therapeutic outcomes.
Anti-angiogenic Therapies
Investigate Tubulysin A's potential in combating tumor growth by inhibiting angiogenesis, a critical process for tumor development and metastasis.
Preclinical and In Vitro Research
Source high-quality Tubulysin A for essential research, including cell cycle analysis, apoptosis studies, and mechanism of action investigations.